Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer

PURPOSE: XL184 (cabozantinib) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models. Early observations of clinical benefit in a phase I study of cabozantinib, which includ...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Kurzrock, Razelle, Sherman, Steven I., Ball, Douglas W., Forastiere, Arlene A., Cohen, Roger B., Mehra, Ranee, Pfister, David G., Cohen, Ezra E.W., Janisch, Linda, Nauling, Forlisa, Hong, David S., Ng, Chaan S., Ye, Lei, Gagel, Robert F., Frye, John, Müller, Thomas, Ratain, Mark J., Salgia, Ravi
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Clinical Oncology 2011
Materias:
Original Reports
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3646303/
https://ncbi.nlm.nih.gov/pubmed/21606412
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.32.4145
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares